Pharmacodynamic outcomes. (A) Mean change in AT levels from baseline. (B) Mean peak TG. Measurements after fitusiran discontinuation +28 days were excluded. Measurements from start date of heparin, AT concentrate, and FXa inhibitor to the final date on which those products were administered plus 5 half-lives of that specific product were excluded. Measurements in the period of missing at least 2 consecutive fitusiran doses were excluded. Only central laboratory assessments were taken into account. SE, standard error.